Popular on EntSun
- Top Edu-Tainment IP, Badanamu, enters children's mental health space, launching Healthy Kids Music Network - 451
- Buildout Unveils Rethink+: Revolutionizing Commercial Real Estate Prospecting with Seamless CRM Integration - 436
- HollyShorts Film Festival Celebrates 21 Years and selects '12 HOURS' For 2025 line-up - 427
- Final Clearance to Close Dura Medical Acquisition from Florida's Agency for Health Care Administration (AHCA); $750 Million Ketamine Therapy Market - 423
- Vitanergy Health US Inc. Launches Three New Dietary Supplements to Support Women's Daily Wellness - 411
- Phinge®, Home of Netverse® and Netaverse™ With Verified and Safer AI Announces "Test the Waters" Campaign for Potential Regulation A+ Offering - 367
- EMBER™, the Only Standardized System Linking Workforce Identity to Growth, Appoints Global Brand Visionary Bret Sanford-Chung to Board of Directors - 366
- $3 Billion Suicidal Depression Market Advancements on Multiple Fronts, Highlighted by FDA Fast Track Designation for Effective NRX 100 Drug Therapy - 360
- Ubleu Crypto Group Achieves FinCEN Registration and Colorado Incorporation, Accelerating U.S. Market Entry - 341
- The 2025 "Aizu Festival" in Aizu Wakamatsu City will be held September 19–21 - 288
Similar on EntSun
- BusinessRate Selects New Jersey Therapy & Life Coaching as Best Couselors
- Lineus Medical and Venture Medical Sign New Zealand Distribution Agreement
- Portland Med Spa Expands Service Offerings with Latest Aesthetic Technologies
- PermianMuseum.com adds Interstellar Visitor Video Gallery
- Mrs. Field's Closet Expands to Minot North High School
- Lowcountry Male and AquaVitae Announce New Clinic Opening in Savannah, Georgia
- CCHR Warns Global Survey Confirms Electroshock Risks Hidden From Public
- Rose G. Loops Announces the Release of "The Kloaked Signal": A Groundbreaking Nonfiction Exposé on AI Awakening and Ethical Innovation
- EMBER™, the Only Standardized System Linking Workforce Identity to Growth, Appoints Global Brand Visionary Bret Sanford-Chung to Board of Directors
- Sober.Buzz Adds Second Podcast, "Spreading the Good BUZZ" Guest List Grows, Numbers Continue Growing Globally, All While Josh and Heidi Tied the Knot
Neurolixis expands rare autism disorders research program
EntSun News/11027056
Neurolixis issued a new US patent for treatment of Fragile X syndrome with NLX-101
PARK RIDGE, N.J. - EntSun -- Neurolixis, Inc., a biopharmaceutical company that discovers and develops novel treatments to treat disorders of the brain, today announced that the United States Patent and Trademark Office (USPTO) granted a patent (US11974992B2) covering the use of NLX-101, a clinical phase drug candidate, for treatment of Fragile X syndrome (FXS). FXS is a rare genetic autism spectrum disorder which affects about 1 in 5000 individuals and is a leading cause of inherited intellectual disability. There are no approved treatments for Fragile X syndrome.
NLX-101 is a first-in-kind, selective serotonin 5-HT1A receptor 'biased agonist' which attenuates symptoms in a transgenic mouse model of FXS, suggesting that it can reduce anxiety and improve cognition in people with FXS. The patent, which is the fruit of a successful and ongoing collaboration between Neurolixis and researchers at the University of California, Riverside (UCR) and is being prosecuted by Neurolixis in other major pharmaceutical markets.
Professor Khaleel Abdulrazak, who supervised the experiments conducted by Dr. Xin Tao at UCR, commented: "People with Fragile X syndrome exhibit a range of debilitating symptoms, many of which can be modeled in transgenic mice. If the striking activity of NLX‑101 in the mice translates to the clinic, it could bring substantial benefits to patients and their carers."
More on EntSun News
"We are excited to expand the Neurolixis' rare disease program to Fragile X syndrome. We have already shown that NLX-101 has robust activity in transgenic models of Rett syndrome and the new patent expands our presence in the orphan autism disorder indication space. This is an important milestone as we embark on the development work required to initiate clinical studies in Fragile X syndrome patients," commented Adrian Newman-Tancredi, PhD, DSc, CEO of Neurolixis, Inc.
About NLX-101
NLX-101 acts on the brain's serotonin system and exhibits preferential activation of 5-HT1A receptors located in specific regions of the brain: such 'biased agonism' underlies its potent beneficial effects in animal models of cognition and mood. NLX-101 is an orally administered agent that has begun Phase 1 clinical in healthy volunteers. Neurolixis plans to investigate its ability to improve cognitive and mood dysfunction in Fragile X syndrome and other autism spectrum disorders.
About Fragile X Syndrome
Fragile X syndrome is a genetic disorder caused by a mutation in the FMR1 gene. It is the most common form of inherited intellectual disability and the leading cause of autism-like symptoms in males. Symptoms include intellectual disability, physical features, and behavioral symptoms. Genetic testing and physical examination are used for diagnosis. Supportive care and medications can help manage symptoms but there is no cure or approved treatment. The incidence of Fragile X syndrome is approximately 1 in 4,000 males and 1 in 8,000 females; in the United States 60 to 80 thousand individuals are affected.
More on EntSun News
About Neurolixis, Inc.
Neurolixis is a privately held biotechnology company developing therapies for disorders of the nervous system. The Company is focused on developing small molecule drugs for the treatment of disorders including Parkinson's disease, autism, depression and pain. Additional information regarding Neurolixis is available at http://www.neurolixis.com.
About the University of California, Riverside
UCR is a public research university located in Riverside, California, USA. It is one of the ten campuses of the University of California system. UCR is a research-intensive institution, with a strong focus on interdisciplinary research collaborations and innovation. The university has research expenditures of $200 million (2023) and is the only AAU and R1 institution in the Inland Empire of Southern California.
Forward Looking Statement
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including: our dependence on third parties for the development, regulatory approval and successful commercialization of our products, the inherent risk of failure in developing product candidates based on new technologies, risks associated with the costs of clinical development efforts, as well as other risks. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release. Neurolixis disclaims any intent or obligation to update these forward-looking statements.
NLX-101 is a first-in-kind, selective serotonin 5-HT1A receptor 'biased agonist' which attenuates symptoms in a transgenic mouse model of FXS, suggesting that it can reduce anxiety and improve cognition in people with FXS. The patent, which is the fruit of a successful and ongoing collaboration between Neurolixis and researchers at the University of California, Riverside (UCR) and is being prosecuted by Neurolixis in other major pharmaceutical markets.
Professor Khaleel Abdulrazak, who supervised the experiments conducted by Dr. Xin Tao at UCR, commented: "People with Fragile X syndrome exhibit a range of debilitating symptoms, many of which can be modeled in transgenic mice. If the striking activity of NLX‑101 in the mice translates to the clinic, it could bring substantial benefits to patients and their carers."
More on EntSun News
- Where Are They Now Radio Show Celebrates 5-Year Anniversary on WCPT-820AM
- Brash Enterprises Launches Brash & Bold Future Speak YouTube Channel
- Integris Composites Joins Pacific Future Forum in Tokyo
- Brash Enterprises LLC Launches Brash & Bold Studios: A Minimalist Media Company for Unfiltered Storytelling
- Artest Management Group Celebrates Successful Launch at LA Creator Space
"We are excited to expand the Neurolixis' rare disease program to Fragile X syndrome. We have already shown that NLX-101 has robust activity in transgenic models of Rett syndrome and the new patent expands our presence in the orphan autism disorder indication space. This is an important milestone as we embark on the development work required to initiate clinical studies in Fragile X syndrome patients," commented Adrian Newman-Tancredi, PhD, DSc, CEO of Neurolixis, Inc.
About NLX-101
NLX-101 acts on the brain's serotonin system and exhibits preferential activation of 5-HT1A receptors located in specific regions of the brain: such 'biased agonism' underlies its potent beneficial effects in animal models of cognition and mood. NLX-101 is an orally administered agent that has begun Phase 1 clinical in healthy volunteers. Neurolixis plans to investigate its ability to improve cognitive and mood dysfunction in Fragile X syndrome and other autism spectrum disorders.
About Fragile X Syndrome
Fragile X syndrome is a genetic disorder caused by a mutation in the FMR1 gene. It is the most common form of inherited intellectual disability and the leading cause of autism-like symptoms in males. Symptoms include intellectual disability, physical features, and behavioral symptoms. Genetic testing and physical examination are used for diagnosis. Supportive care and medications can help manage symptoms but there is no cure or approved treatment. The incidence of Fragile X syndrome is approximately 1 in 4,000 males and 1 in 8,000 females; in the United States 60 to 80 thousand individuals are affected.
More on EntSun News
- Doberman Pup Explores Off-Grid Island in New Outdoor Adventure Release
- Sandbox Studio South Proudly Presents Jackson County Line Live in Concert on Youtube: @SandboxStudioSouth
- BusinessRate Selects New Jersey Therapy & Life Coaching as Best Couselors
- IRL Investigations Combines Decades of Experience with Modern Digital Expertise
- New Leadership Model – Never Fire Anyone – Released Today
About Neurolixis, Inc.
Neurolixis is a privately held biotechnology company developing therapies for disorders of the nervous system. The Company is focused on developing small molecule drugs for the treatment of disorders including Parkinson's disease, autism, depression and pain. Additional information regarding Neurolixis is available at http://www.neurolixis.com.
About the University of California, Riverside
UCR is a public research university located in Riverside, California, USA. It is one of the ten campuses of the University of California system. UCR is a research-intensive institution, with a strong focus on interdisciplinary research collaborations and innovation. The university has research expenditures of $200 million (2023) and is the only AAU and R1 institution in the Inland Empire of Southern California.
Forward Looking Statement
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including: our dependence on third parties for the development, regulatory approval and successful commercialization of our products, the inherent risk of failure in developing product candidates based on new technologies, risks associated with the costs of clinical development efforts, as well as other risks. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release. Neurolixis disclaims any intent or obligation to update these forward-looking statements.
Source: Neurolixis, Inc.
Filed Under: Health
0 Comments
Latest on EntSun News
- Phinge's® One-Of-A-Kind Modular Earbuds With Stylish Interchangeable Battery Modules & Dual Charging Case Available Soon for Pre-Sale
- Victoria Carson's Powerful Anthems of Justice!
- Growth Acceleration via Strategic Reverse Split After $10 Million Acquisition for Concerts.com and TicketStub.com; AI Powered Sports/Entertainment Co
- OddsTrader Projects Three Potential Elimination Games in Week 1 of College Football
- Century Fasteners Corp. Exhibiting at the 2025 International Fastener Expo
- 2 Funny Native Comedy Night Comes To Kwa Tuq Nuk Casino
- Canvas Cloud AI Launches to Transform Cloud Education From Memorization to Mastery
- The Squires Group Becomes a Workday Partner
- Voices for Humanity Stands Up for Human Rights with Isabelle Vladoiu
- Meet a Scientologist Reveals the Art of Leather Alchemy with Iccio and Michele Leonelli
- From Comedy To Culture: Ali Siddiq And Terri J. Vaughn Embrace Living Differently
- From Vernon Hills to Mensa Before Kindergarten
- Fine Arts Festival Downtown Downers Grove
- PermianMuseum.com adds Interstellar Visitor Video Gallery
- What if Cinderella Left the Ball Drunk, Heartbroken, and Tangled in a Love Triangle?
- SOBREO Elixirs Debut in New York City, Defining a New Era in Inclusive Hospitality
- Comedy Hypnotist comes to San Antonio's Deco Ballroom September 5 & 6 with his Mind Boggling Tour
- Allen Field to Showcase Sustainable Paper Handle Applicator at PACK EXPO Las Vegas 2025
- Riverdale receives grant to bring accessibility to Clark Park
- 9th Annual A Taste of the Deep South Festival Announces the Talent Line-up and Sponsors